Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer

International Journal of Women's Health

Volumn 6, Issue 1, 2014, Pages 289-300

  Davidson, Brittany A ^a   Secord, Angeles Alvarez ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Antiangiogenic agents; Ovarian carcinoma; Pazopanib

Indexed keywords

BEVACIZUMAB; CEDIRANIB; COLONY STIMULATING FACTOR 1; DOXORUBICIN; FIBROBLAST GROWTH FACTOR; GEMCITABINE; INTERLEUKIN 2; NINTEDANIB; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE LCK; STEM CELL FACTOR RECEPTOR; TREBANANIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; CONFUSION; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HEART VENTRICLE EJECTION; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER DISEASE; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UTERINE TUBE CARCINOMA; VOMITING;

EID: 84897899201     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S49781     Document Type: Review

References (91)

1. International Agency for Research on Cancer. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 - fact sheets by population. Available from: http://globocan.iarc.fr/Pages/ fact_sheets_population.aspx. Accessed December 22, 2013.
2. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200.
3. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320-1329.
4. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Eng J Med. 2006;354(1):34-43.
5. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020-1026.
6. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Eng J Med. 2011;365(26):2473-2483.
7. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Eng J Med. 2011;365(26):2484-2496.
8. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878-1886.
9. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13(1):73-80.
10. Linderholm BK, Lidbrink E, Tallroth E, et al. Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel. Breast. 2013;22(6):1142-1147.
11. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997;15(1):187-192.
12. Clinicaltrials.gov Available at: clinicaltrials.gov. Accessibility verified January 31, 2014
13. FIGO Committee on Gynecologic Oncology: Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009; 105(1):3-4
14. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Available from: http://www.nccn.org/professionals/ physician_gls/pdf/ovarian.pdf. Accessed December 22, 2013.
15. Chan J, Brady M, Penson R, et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262. Oral presentation at: 18th European Society of Gynaecological Oncology International Meeting; October 19-22, 2013; Liverpool, UK.
16. Monk BJ, Poveda A, Vergote I, et al. A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. Poster presented at: European Society for Medical Oncology Cancer Congress; September 27-October 1, 2013; Amsterdam, Netherlands.
17. duBois A, Floquet A, Kim J, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16). Am Soc Clin Oncol. 2013; 31 Suppl:LBA5503.
18. Ledermann JA, Perren TJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 21717) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Poster presented at: European Society for Medical Oncology Cancer Congress; September 27-October 1, 2013; Amsterdam, Netherlands.
19. du Bois A, Vergote I, Wimberger P, et al. Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group. Br J Cancer. 2012;106(4):629-632.
20. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Eng J Med. 1991;324(1):1-8.
21. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84(24):1875-1887.
22. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143(2):401-409.
23. Zätterström UK, Brun E, Willén R, Kjellén E, Wennerberg J. Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head Neck. 1995;17(4):312-318.
24. de Jong JS, van Diest PJ, Baak JP. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology. 2000;36(4):306-312.
25. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94(12):883-893.
26. Rubatt JM, Darcy KM, Hutson A, et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112(3):469-474.
27. Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res. 1999;5(3):587-591.
28. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005;8(2):169-182.
29. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121(1):230-238.
30. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007;2:251-275.
31. Gadducci A, Viacava P, Cosio S, et al. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res. 2003;23(3C):3001-3008.
32. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6(4):373-378.
33. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15(6):539-547.
34. Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 2004;24(3b):1973-1979.
35. Wild R, Dings RP, Subramanian I, Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer. 2004;110(3):343-351.
36. Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene. 2001;20(41): 5878-5887.
37. Sallinen H, Heikura T, Laidinen S, et al. Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(9):1498-1505.
38. Henriksen R, Funa K, Wilander E, Bäckström T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 1993;53(19):4550-4554.
39. Tsutsumi S, Ishibashi K, Uchida N, et al. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study. Oncology. 2012;83(3):151-157.
40. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26(33):5326-5334.
41. McCann GA, Smith B, Backes FJ, et al. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen? Gynecol Oncol. 2012;127(2):362-366.
42. American Cancer Society. Pazopanib. Available at: http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/pazopanib. Accessed January 31, 2014.
43. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012-2021.
44. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111(9):1287-1295.
45. Merritt WM, Nick AM, Carroll AR, et al. Bridging the gap between cytotoxic and biologic therapy with metronomic topote can and pazopanib in ovarian cancer. Mol Cancer Ther. 2010;9(4): 985-995.
46. Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006;103(51): 19478-19483.
47. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008;51(15):4632-4640.
48. US Food and Drug Administration. FDA approves new treatment for advanced form of kidney cancer [press release]. Silver Spring, MD: US FDA; 2009 [October 19]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187174.htm. Accessed December 22, 2013.
49. US Food and Drug Administration. FDA approves Votrient for advanced soft tissue sarcoma [press release]. Silver Spring, MD: US FDA; April 26, 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302065.htm. Accessed December 22, 2013.
50. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12): 4220-4227.
51. Burris HA 3rd, Dowlati A, Moss RA, et al. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther. 2012;11(8): 1820-1828.
52. Tan AR, Dowlati A, Jones SF, et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist. 2010;15(12):1253-1261.
53. de Jonge MJ, Hamberg P, Verweij J, et al. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs. 2013;31(3): 751-759.
54. Kerklaan BM, Lolkema M, Devriese LA, et al. Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors. J Clin Oncol. 2013;31 Suppl:2536.
55. Plummer R, Madi A, Jeffels M, et al. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71(1):93-101.
56. Duska, LR. A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer. Available from: http://clinicaltrials.gov/show/NCT01610206. NLM identifier: NCT01610206. Accessed: January 31, 2014.
57. Negrier S, Imbs DC, Perol D, et al. Pazopanib (P) and bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors: Phase I combination study final analysis. J Clin Oncol. 2013;31 Suppl:4574.
58. Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119(1):32-37.
59. Response Evaluation Criteria in Solid Tumors. Available at: http://www. recist.com Accessibility verified: January 31, 2014.
60. Oaknin A, Gonzalez-Martin A, Garcia Y, et al. Phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): a Spanish Ovarian Cancer Group (GEICO) study. J Clin Oncol. 2012;30 Suppl:5068.
61. J Sehouli. Pazopanib and weekly topotecan in patients recurrent ovarian cancer (TOPAZ). Available from: http://clinicaltrials.gov/ct2/show/NCT0 1600573?term=NCT01600573&rank=1. NLM identifier: NCT01600573. Accessed January 31, 2014.
62. National Cancer Institute, Naples. Weekly paclitaxel with or without pazopanib in platinum resistant or refractory ovarian cancer (MITO-11). Available from: http://clinicaltrials.gov/ct2/show/NCT01644825?term =NCT01644825&rank=1. NLM identifier: NCT01644825. January 31, 2014.
63. SCRI Development Innovations, LLC. Study of pazopanib and doxil in patients with advanced relapsed platinum-sensitive or platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01035658?term=NCT010 35658&rank=1. NLM identifier: NCT01035658. Accessed January 31, 2014.
64. Cambridge University Hospitals NHS Foundation Trust. HYPAZ: Hypertension induced by pazopanib. Available from: http://clinicaltrials.gov/ct2/show/NCT01392352?term=NCT01392352&rank=1. NLM identifier: NCT01392352. Accessed January 31, 2014.
65. Eichbaum M, Mayer C, Eickhoff R, et al. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer. 2011;11:453.
66. Zang R, Wu L, Zhu J, et al. Pazopanib (Paz) monotherapy in Asian women who have not progressed after first-line chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol. 2013;31 Suppl:5512.
67. Guo J, Jin J, Huang Y, et al. Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ). J Clin Oncol. 2013;31 Suppl 6:366.
68. Friedlander MK, Meier W, Lesoin A, et al. Quality of life in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC) receiving either pazopanib monotherapy or placebo after first-line chemotherapy: AGO-OVAR16 results. Poster presented at: European Society for Medical Oncology Cancer Congress; September 27-October 1, 2013; Amsterdam, the Netherlands.
69. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. EurJ Cancer. 2013;49(6):1287-1296.
70. Qi WX, Lin F, Sun YJ, et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol. 2013;71(2):431-439.
71. Shibata SI, Chung V, Synold TW, et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2013;19(13):3631-3639.
72. Sideras K, Menefee ME, Burton JK, Erlichman C, Bible KC, Ivy SP. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol. 2010;28(19):e312-e313.
73. Semrad TJ, Eddings C, Dutia MP, Christensen S, Lara PN Jr. Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs. 2013;24(6):636-640.
74. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leuko encephalopathy syndrome. N Eng J Med. 1996;334(8):494-500.
75. Schwartz RB, Jones KM, Kalina P, et al. Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol. 1992;159(2):379-383.
76. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010;11(5):465-475.
77. Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010;117(3):497-504.
78. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol. 2007;105(1): 3-6.
79. Glaxo Smith Kline. Investigator's Brochure for Pazopanib (GW786034) for Oncology and Opthalmic Indications. 10th ed. Brentford, UK: GlaxoSmithKline; 2013.
80. Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharm Ther. 2010;88(5):652-659.
81. Xu CF, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 2012;23(9):2470-2471.
82. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13(8):827-837.
83. Goede V, Coutelle O, Neuneier J, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010;103(9):1407-1414.
84. Nixon AB, Pang H, Starr MD, et al. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB 80303 (Alliance). Clin Cancer Res. 2013;19(24): 6957-6966.
85. Imperial College London. [18F]Fluciclatide-PET, pazopanib and paclitaxel in ovarian cancer (PAZPET-1). Available from: http://clinicaltrials.gov/ct2/show/NCT01608009?term=NCT01608009&rank=1. NLM identifier: NCT01608009. Accessed January 31, 2014.
86. European Organisation for Research and Treatment of Cancer EORTC. Pazopanib hydrochloride, paclitaxel, and carboplatin in treating patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01402271?term=NCT01402271&rank=1. NLM identifier: NCT01402271. Accessed January 31, 2014.
87. Grande E, Casanovas O, Earl J, et al. sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis. J Clin Oncol. 2013; 31 Suppl:4140.
88. Necchi A, Mariani L, Zaffaroni N et al. Pazopanib in advanced and platinum resistant urothelial cancer: an open-label, single group phase 2 trial. Lancet Oncol. 2012; 13(8):810-816.
89. Kattan MW, Chakrabarti D, Bhatt K, Mehmud F, Sternberg CN, Motzer RJ. Development and internal validation of a prognostic nomogram for overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib (PAZ). J Clin Oncol. 2013;31(6):380.
90. Dy GK, Infante JR, Eckhardt SG et al. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Invest New Drugs. 2013; 31(4):891-899.
91. Fasolo A, Sessa C, Bauer JA et al. Phase Ib clinical and pharmacological study of multiple schedules of pazopanib and epirubicin in patients with advanced solid tumors. Presented at: 2010 American Society of Clinical Oncology Annual Meeting. 4-8 June; Chicago, IL.